Myeloid maturation arrest is a typical feature of myelodysplastic syndrome. The occurrence of such a finding in patients who earlier received anthracycline-based chemotherapy usually prompts the suspicion of therapyrelated myelodysplastic syndrome. Here, we report a case of relapsed aggressive lymphoma that, after successful autologous hematopoietic stem cell transplant (HSCT), had progressive pancytopenia and myeloid maturation arrest in the BM. The final diagnosis turned out to be extrapulmonary tuberculosis (TB), and empirical anti-TB treatment resulted in the resolution of pancytopenia and the restoration of myeloid maturation. We review the literature and briefly discuss on the evaluation and management of patients with such unique features.
A 63-year-old diabetic male visited our hospital in June 2007 because of an enlarged neck mass, productive cough, and fever. Pulmonary TB and stage IIIB diffuse large B-cell lymphoma were diagnosed concurrently. After standard courses of rituximab-based combination immunochemotherapy and anti-TB therapy, complete remission was achieved for both lymphoma and pulmonary TB. Unfortunately, recurrence of lymphoma was noted 11 months later. Salvage chemotherapy resulted in a second remission and the patient underwent autologous HSCT successfully in March 2009. After engraftment, his Hb level and platelet count were maintained at around 8-9 g/100 mL and 50-60 Â 10 9 /L, respectively, whereas his WBC count was normal.
About two and a half months after the transplant, progressive pancytopenia developed, with nadir counts as follows-WBC count: 1600/mL; 59% neutrophils; Hb: 7.5 g/100 mL; and platelets: 10 Â 10 9 /L. CMV disease, one of the more common infectious complications after HSCT, which could lead to pancytopenia, was carefully excluded based on serological tests including PCR for CMV DNA detection. BM aspiration was performed in June 2009, which showed a normocellular marrow with a moderately decreased number of megakaryocytes. There was prominent myeloid maturation arrest ( Figure 1a ). No apparent dyserythropoiesis or lymphoma cell infiltration was seen. Therapy-related myelodysplastic syndrome was considered as a possibility, as 42 years had passed since the patient received the first dose of anthracycline. However, BM biopsy disclosed profuse granulomatous inflammation shown by diffuse infiltration of histiocytes (Figure 1b) . On immunohistochemical staining, these cells were strongly CD68 positive (Figure 1c) . Such findings and his past history raised the suspicion of extrapulmonary TB. A therapeutic trial with anti-TB drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) was started in spite of a negative finding on acid-fast stain of marrow tissue and normal appearance on chest X-ray film. One month after treatment, his hemogram improved significantly-WBC count: 4100/mL; 57% neutrophils; Hb: 9.6 g/100 mL; and platelets: 100 Â 10 9 /L. A follow-up BM study showed restoration of normal myelopoiesis with good maturation (Figure 1d) .
Unfortunately, the clinical course was further complicated by huge perianal and genital abscesses. The infection was caused by HSVs. Poor wound healing resulted in Enterococcus faecium septicemia and later, fulminant infection-associated hemophagocytic syndrome. He died from his illness in spite of aggressive therapeutic intervention. No evidence of lymphoma recurrence was documented at the time of his death.
HSCT recipients usually have severely impaired cellular immunity because of their underlying disease, the steroid they had received during treatment, and pretransplant high-dose chemotherapy. Therefore, an increased incidence of mycobacterial infection might be expected. Large series reported the incidences of TB in HSCT recipients ranging from 0.1 to 5%, with the highest incidence usually seen in endemic areas. [1] [2] [3] [4] Our patient had the unique manifestation of pancytopenia and maturation arrest of myeloid cells in the BM as the initial presentation of extrapulmonary TB. Myeloid maturation arrest can be seen in patients with active infection, but there has been no report in the literature regarding its association with TB. We used BM granuloma as the principal hint of mycobacterial infection. BM granuloma, an infrequent finding in a BM biopsy, could be caused by drugs, infections including mycobacteria, Rhodococcus, Nocardia, histoplasmosis, fungi, CMV, and EB virus, or systemic disorders such as malignant neoplasms, sarcoidosis, and connective tissue diseases. 5 Among them, TB is the most common causative etiology according to several major studies. 5, 6 Definite diagnosis of TB in such patients, however, would be difficult. Caseating necrosis is not a common finding in a tuberculous BM biopsy, whereas the presence of acid-fast bacilli is rare. 6 As our country is an endemic area, we considered TB the most likely presumptive diagnosis. Although we did not find direct evidence of mycobacterial infection in the patient, the temporal association between timely initiation of anti-TB therapy and restoration of myelopoiesis justifies the causal relationship.
The diagnosis of extrapulmonary TB in HSCT recipients is often delayed as a result of the host's immunocompromised status, varied and nonspecific clinical manifestations, prolonged duration required for isolation of mycobacterium, and coexistence of multiple infectious pathogens. Therefore, their clinical management demands a high index of suspicion and early appropriate intervention.
In conclusion, our case serves as a reminder that maturation arrest of myeloid elements in the marrow could actually be a manifestation of extrapulmonary TB in the post-HSCT setting. Physicians must consider TB as a differential diagnosis under such circumstances, especially in endemic areas. 
